Why the study?
Is circulating NRG-1β associated with disease severity and adverse outcomes in patients with chronic heart failure?
Is circulating NRG-1β associated with disease severity and adverse outcomes in patients with chronic heart failure?
Serum NRG-1β is identified as a novel biomarker associated with disease severity and adverse outcomes in chronic heart failure.
NRG-1β may refine HF prognostication; hypothesis-generating and requires prospective validation before clinical adoption.
Circulating NRG-1beta is independently associated with heart failure severity and risk of death or cardiac transplantation. These findings support a role for NRG-1/ErbB signaling in human heart failure and identify serum NRG-1beta as a novel biomarker that may have clinical applications.
No takes yet. Share an insight, caveat, or question.
Ky et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: